novo nordisk semaglutide fda Novo's Wegovy adds another indication with approval Novo Nordisk withdraws FDA application

Regulatory context adds another layer

A few reviews suggest the product did not work as expected

Established Track Record: Because it has been on the market since 2017, doctors have a deeper understanding of its long-term effects compared to newer "twincretins" like Tirzepatide

The UK Medicines and Healthcare products Regulatory Agency (MHRA) is investigating over 560 reports of pancreatitis associated with GLP-1 medications, including Ozempic (semaglutide), Wegovy (semaglutide), and Mounjaro (tirzepatide)

The American Society of Anesthesiologists recommends temporarily halting the use of GLP-1 medications before planned procedures

That is 35-plus years old with no modern trial confirming it lowers scalp DHT